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Abstract
Fasciola hepatica secretes cathepsin L proteases that facilitate the penetration of the parasite through the tissues of its host, and also
participate in functions such as feeding and immune evasion. The major proteases, cathepsin L1 (FheCL1) and cathepsin L2 (FheCL2) are
members of a lineage that gave rise to the human cathepsin Ls, Ks and Ss, but while they exhibit similarities in their substrate specificities to
these enzymes they differ in having a wider pH range for activity and an enhanced stability at neutral pH. There are presently 13 Fasciola
cathepsin L cDNAs deposited in the public databases representing a gene family of at least seven distinct members, although the temporal
and spatial expression of each of these members in the developmental stage of F. hepatica remains unclear. Immunolocalisation and in situ
hybridisation studies, using antibody and DNA probes, respectively, show that the vast majority of cathepsin L gene expression is carried out
in the epithelial cells lining the parasite gut. Within these cells the enzyme is packaged into secretory vesicles that release their contents into
the gut lumen for the purpose of degrading ingested host tissue and blood. Liver flukes also express a novel multi-domain cystatin that may be
involved in the regulation of cathepsin L activity. Vaccine trials in both sheep and cattle with purified native FheCL1 and FheCL2 have
shown that these enzymes can induce protection, ranging from 33 to 79%, to experimental challenge with metacercariae of F. hepatica, and
very potent anti-embryonation/hatch rate effects that would block parasite transmission. In this article we review the vaccine trials carried out
over the past 8 years, the role of antibody and T cell responses in mediating protection and discuss the prospects of the cathepsin Ls in the
development of first generation recombinant liver fluke vaccines.
q 2003 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.
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1. Introduction
The trematode parasites Fasciola hepatica (temperate)
and Fasciola gigantica (tropical) are the causative agents of
liver fluke disease (fasciolosis) in cattle and sheep. Infection
causes world-wide economic losses of approximately
US$2,000 million annually to the agricultural sector
(Spithill et al., 1999a). Fasciolosis is also an emerging
pathogen of humans particularly in the South American
countries Bolivia, Peru and Equador, in Egypt and Iran
(O’Neill et al., 1998; Mas-Coma et al., 1999; Rokni et al.,
2002). It is estimated that 2.4 million people are infected
with liver fluke world-wide (Mas-Coma et al., 1999).
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Fasciolosis is acquired following the ingestion of
vegetation or water contaminated with the encysted
infectious liver fluke larvae, known as metacercariae.
Metacercariae excyst in the intestines, burrow through the
intestinal wall and migrate into the liver tissue where they
spend about 8–12 weeks feeding on host tissue and blood
and consequently causing extensive haemorrhaging and
perforations. This acute stage of disease can result in death
in highly infected sheep, but death is rarely seen in cattle.
After this period the parasites move into the bile ducts
where they complete their growth and maturation. The
hermaphroditic adult liver flukes puncture the wall of the
bile duct and feed on blood that provides the nutrient for
the production of enormous numbers of eggs that are carried
into the intestine with the bile fluids and are passed onto
pasture with the faeces. An aquatic larval stage hatches from
the eggs and infects an intermediate mud-snail host, such as
Lymnaea truncatula. After several developmental and
multiplication stages within the snail the parasites emerge
and become encysted on vegetation and thus continue the
cycle (Andrews, 1999).
A number of chemicals are commercially available for
the treatment of animal fasciolosis, including closantal,
clorsulon, rafoxanide, nitroxynil and triclabendazole (see
Fairweather and Boray, 1999). Following dosing, the
therapeutic concentration of these drugs in the blood is
reached for approximately 1–2 days and hence only current
parasitic infections are cleared. Animals on contaminated
pastures are then susceptible to re-infection. Triclaben-
dazole requires particular mention since this is the only drug
effective against early stage parasites, i.e. the stages that
migrate through the liver and induce acute fasciolosis. The
drug was launched in Ireland in 1983 under the brand name
Fasinex (Ciba-Geigy, now Novartis Animal Health) and has
enjoyed substantial commercial success. However, in 1995
an anonymous letter to the Irish Farmer’s Journal (Anon.,
1995) reported the presence of triclabendazole-resistant
liver flukes on a farm in Co. Sligo, an area where fasciolosis
is endemic. If verified this provides an example of how
quickly (within 12 years) drug resistance to anthelminthics
can appear in the field. Triclabendazole resistance has now
been reported in Australia (Overend and Bowen, 1995;
Fairweather and Boray, 1999), Scotland (Mitchell et al.,
1998) and the Netherlands (Moll et al., 2000; Gaasenbeek
et al., 2001).
Apart from the appearance of drug resistant parasites,
other pressures in the form of EU regulations, consumer
concerns for ‘greener’ food and for animal welfare, and
environmental issues regarding the passage of chemical
residues onto pastures and into waterways will make the
control of helminth diseases, including fasciolosis, with
chemical drugs unsustainable. The future of liver fluke
control will almost certainly depend on the development of
a protective vaccine; the challenge will be to develop and
commercialise such a product that will give a benefit that is
visible to farmers (i.e. enhanced performance of animals,
reduced deaths, etc.) at a competitive price (i.e. at a cost as
low as drug treatments). It must be remembered, however,
that vaccines provide ‘protection’ against infection and
thereby have an advantage over drugs (particularly those
that are effective against the adult liver fluke stages alone)
that only provide a ‘treatment’. Moreover, vaccines are
considered safe and environmentally friendly.
Recent advances in molecular biology (proteomics and
genomics) have made it relatively easy to identify and
isolate potential vaccine components but in the case of liver
flukes there is still a dearth of vaccine candidates that have
been tried and tested in the target species, i.e. sheep and
cattle. Research on a number of molecules including
cathepsin Ls, glutathione S-transferase (GST), leucine
aminpeptidase (LAP) and fatty acid binding proteins
(FABP), however, has demonstrated the feasibility of
inducing protective responses in laboratory and large animal
models (reviewed by Spithill and Dalton, 1998; Spithill
et al., 1999a). This article will review the work of our
laboratory and others on liver fluke cathepsin L proteases
and update the progress towards a vaccine.
2. Biochemical characteristics of cathepsin Ls
Fasciola hepatica cathepsin L proteases were the first of
this class of enzyme to be described in helminths (Smith
et al., 1993). It is now known that this enzyme class is
expressed by all parasitic worms and in many cases they are
secreted and hence are pivotal in the host–parasite inter-
play. However, they appear to be particularly prominent in
trematodes as compared to nematodes where cathepsin
B-like enzymes tend to be expressed in greater amounts
(Tort et al., 1999).
Enzyme activity attributable to cysteine proteases was
detected in our laboratory in extracts of F. hepatica
parasites and ES products over a decade ago (Dalton and
Heffernan, 1989). However, a more recent characterisation
of these extracts using synthetic peptide substrates, such as
Z-Phe-Arg-NHMec, demonstrated that the dominant
activity was cathepsin L-like. Two distinct cathepsin L
proteases have been purified in our laboratory from culture
medium in which adult F. hepatica parasites were incubated
and shown to be the predominant proteolytic activity
secreted by the worms (Smith et al., 1993; Dowd et al.,
1994). Subsequently, transcripts encoding these two major
cathepsin L-like proteases, termed FheCL1 and FheCL2,
have been isolated from cDNA libraries by immunoscreen-
ing with anti-sera prepared against the native enzymes
(Dowd et al., 1997; Roche et al., 1997). These transcripts
encode zymogens with structures that are similar to those of
vertebrate cathepsin Ls in that they consist of a hydrophobic
signal peptide (12–20 residues), a pro-segment (100
residues) and a mature enzyme (200 residues) (see Fig. 1).
Unlike mammalian cathepsin Ls, FheCL1 and FheCL2 do
not possess potential N-glycosylation sites in their mature
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enzyme portion and electrophoretic/immunoblot analyses
suggest that they are not glycosylated.
The substrate specificity of the cathepsin Ls was
examined using synthetic fluorogenic peptide substrates
that are classically used to characterise mammalian
cathepsin Ls, Ss, Ks (Z-Phe-Arg-NHMec), cathepsin B
(Z-Arg-Arg-NHMec) and cathepsin H (Z-Arg-NHMec)
(Barrett and Kirschke, 1981). Both enzymes demonstrated
high catalytic efficiency (kcat/Km) for Z-Phe-Arg-NHMec,
but showed little or no activity against the latter two
substrates. This substrate specificity is consistent with their
grouping with the non-cathepsin B proteases; however,
FheCL2 could also cleave substrates that contained proline
in the P2 position, and the substrate Z-Gly-Pro-Arg is used
to distinguish between FheCL1 and FheCL2 activities
(Dowd et al., 1994, 1997).
The F. hepatica cathepsin L-like proteases are active over
a wide pH range (pH 3.0–8.0), and stability studies
demonstrated that FheCL1 retains 100% of its activity
when incubated at 37 8C for 24 h. In contrast, human
cathepsin L is irreversibly inactivated above pH 7.0, a
property that is thought to protect cells against uncontrolled
proteolysis in the event of accidental leakage from the
lysosomes (Dowd et al., 2000). The stability of the liver fluke
enzymes may reflect the fact that the parasite employs them
to generate a migratory path through a large tissue mass, the
liver, on its way to the bile ducts.
3. The cathepsin L gene family
Early studies by Heussler and Dobbelaere (1994)
indicated that F. hepatica expressed several cathepsin L
genes, but since this report the number of cathespin L cDNA
entries into the public databases has gradually grown so that
at writing there are 13 known F. hepatica cathepsin genes.
The number of F. gigantica cathepsin L entries in
the databases has also grown mainly due to the efforts of
Grams et al. (2001) and Yamasaki et al. (2002), and
unsurprisingly many of these genes appear to be homo-
logues of the F. hepatica genes. The family as it stands is
presented in Fig. 2; some of the encoded polypeptides
Fig. 1. Activation of Ni-NTA-agarose purified P. pastoris-expressed
recombinant FheCL1 at pH 5.5. Purified recombinant FheCL1 resolves as
two bands of 38 (upper) and 34 kDa (lower, arrowed) that represent the full
pre-pro-mature and a truncated pro-mature form of the enzyme,
respectively. While this preparation exhibits cathespin L activity it can
be further activated to the fully processed mature enzyme (last lane on
right) by incubating it for a period of 1–2 h in 0.1 M sodium acetate, pH
5.5. The positions of the major proteins resolved in the gel with respect to
the cathepsin L pro-enzyme are shown schematically and were determined
by N-terminal sequencing.
Fig. 2. Dendrogram of F. hepatica and F. gigantica cathepsin L gene family. Relationship of the cathepsin L cDNAs (public database accession numbers at end
of branches). FheCL1 and FheCL2 are highlighted in bold. Sequences isolated from cDNA from newly excysted juveniles are italicised. Samples were
analysed using 1,000 bootstrap replicates (numbers represent values obtained).
J.P. Dalton et al. / International Journal for Parasitology 33 (2003) 1173–1181 1175
differ in only a few amino acids and may represent alleles
rather than distinct genes. Nevertheless, it is clear that at
least seven different cathepsin L genes are expressed by
these trematodes. Phylogenetic studies of this gene family
revealed that they belong to a clade that includes the
mammalian cathepsin Ls, cathepsin Ss and cathepsin Ks
(the parasite enzymes show 40–55% similarity with the
mammalian homologues) (Tort et al., 1999) Of particular
note is that the newly excysted juvenile (NEJ)-specific
cathepsin L cDNAs (two from F. hepatica and one from
F. gigantica) cluster together in the dendrogram shown in
Fig. 2, which may suggest that cathepsin L expression in
NEJ is limited to two genes whereas in the adult stages
many more genes are expressed.
It is difficult to assess the temporal expression and
localisation of each of the cathepsin L gene products
because their close nucleic acid/amino acid sequences
similarities preclude the development of specific PCR/anti-
body reagents. However, in situ hybridisation studies by
Grams et al. (2001) with F. gigantica and by us with
F. hepatica (Fig. 3) are consistent with immunolocalisation
studies (Smith et al., 1993) and show that the vast majority
of cathepsin L proteases are expressed in the cells lining the
parasite’s guts. It is possible that more than FheCL1 and
FheCL2 proteases are secreted by the parasite, which would
agree with the 2-D electrophoresis analysis by Wijffels et al.
(1994) and Jefferies et al. (2001) that shows the presence of
multiple cathepsin L proteases in adult F. hepatica ES
products. The structure of one of the F. gigantica genes was
recently determined by Yamasaki et al. (2002), and consists
of four exons and three introns of similar size and
arrangement to those found in crustacean and mammalian
cathepsin Ls.
4. Regulation of cathepsin L activity
Enzymatic assays have shown that cathepsin L activity is
expressed in the infective stage of the parasite, the NEJ, in
the immature developmental stages that migrate through the
liver parenchyma and in adults that reside in the bile ducts
(Carmona et al., 1993; Smith et al., 1993). A proteomics
approach to characterising NEJ proteins confirmed the
presence of cathepsin L proteases in this stage (Tkalcevic
et al., 1995) and now full-length F. hepatica and F. gigantica
NEJ-specific cathepsin L sequences are available in the
public databases (Fig. 2).
As mentioned above the proteases are synthesised in the
epithelial cells that line the parasite gut (Fig. 3). Within
these cells the proteases are packaged into secreted vesicles
in high concentration ready for secretion. During trafficking
to these secretory vesicles the activity (and stability) of the
cathespin Ls is controlled by the presence of the pro-peptide
on the protein (as has been demonstrated for mammalian
cathepsin Ls) (Roche et al., 1997). It remains unclear
whether the proteases are activated before they reach the
vesicles or following their secretion by the NEJ and by the
adult.
It is possible that other mechanisms exist to protect the
parasite’s cells from unwanted protease activity. Recently,
Khaznadji, Collins, Dalton and Moire (unpublished)
discovered a novel molecule that contains five cystatin
Fig. 3. Localisation of cathepsin L proteases by in situ hydridisation. Light micrographs showing the expression of cathepsin L protease in transverse sections
(20 mM) of adult F. hepatica. In situ hybridisation was performed using digoxigenin-labelled DNA probes to cathepsin L protease gene. Specific sense
[50-tgtggctcctgttgggcattc-30] and anti-sense [50-ggattcggtttccaatcc-30] primers were designed to amplify a region of 195 bp (including primers) from F. hepatica
cathepsin L genes. Each probe (sense strand and anti-sense strand) was generated using asymmetrical PCR and digoxigenin-labelled di-nucleotide
triphosphates (dNTPs) (Roche Diagnostics); cryostat sections were stained following overnight hybridisation at 50 8C. Gene expression can be seen as a dark
red/brown chromogen formed by substrate cleavage by alkaline phosphatase conjugated to anti-digoxigenin antibodies bound to the probes. All sections were
treated in the same way except that A and C were exposed to the sense strand probes (negative controls) whereas B and D were exposed to the anti-sense strand
probes. Asterisks indicate gut lumen and arrows indicate positive staining/cathepsin L expression. (A) Low power micrograph showing unstained gut. Mag.
£ 20. (B) Low power micrograph showing positive staining in four gut. Mag. £ 20. (C) High power micrograph showing several unstained gut. Mag. £ 40.
(D) High power micrograph showing strong positive staining in 2 gut. Mag. £ 40.
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domains, two of which are potent inhibitors of cathepsin L
(the structure of the other three cystatin domains appears to
be degenerate, Fig. 4). This multi-domain cystatin is
expressed in NEJ and adult flukes but its expression is
greater in the former stage. The cathepsin L protease may be
required in large amounts by the NEJ to allow them quickly
to invade the host intestinal wall following excystment, and
a corresponding cystatin inhibitor may be necessary to
protect the parasite from its own proteolytic activity during
its storage or after secretion.
5. Functions of the cathepsin Ls
Cathepsin Ls that are secreted into the gut lumen
following ingestion of host blood and liver tissue perform
the task of digesting host tissues. The breakdown products
of this endoproteolysis are then absorbed into the epithelial
cells where they may undergo further degradation by
dipeptidyl peptidases and aminopeptidases to amino acids
that are then used in the anabolism of parasite proteins, or in
the case of adults, in the production of eggs (Tort et al.,
1999).
Because liver flukes possess a blind-ending intestine,
the contents of the gut must be emptied by frequent
regurgitation (approximately every 3 h). Accordingly, the
protease must reach the outside tissue where they may carry
out additional important functions for the parasite, including
the excavation of a migratory tract. In this context, we have
demonstrated that liver fluke cathepsin Ls can efficiently
cleave interstitial matrix proteins such as fibronectin,
laminin and native collagen (Berasain et al., 1997). We
have also shown that the parasite cathepsin Ls can cleave
immunoglobulins precisely in the hinge region (thus
separating the Fab from the Fc regions) and prevent the
antibody-mediated attachment of eosinophils to the parasite
surface and hence may aid in protecting the parasite from
immune attack (Carmona et al., 1993; Smith et al., 1993;
Berasain et al., 1997).
More recently, however, we have proposed that the
secreted cathepsin Ls may be involved in suppression and/or
modulation of Th1 immune responses and induction of non-
protective host Th2 responses. An analysis of cytokine
production by antigen-stimulated spleen cells of F. hepatica-
infected mice showed that these are predominantly of the
Th2 type, i.e. production of interleukin (IL)-4, IL-5 and
IL-10, but little or no IFN-g (O’Neill et al., 2000). This is
consistent with immunological observations in cattle which
show that in the early stages of infections mixed Th1/Th2
responses are observed but as infection progresses, a Th2
Fig. 4. The novel multi-domain F. hepatica cystatin. The Nematode cystatins-like Onchocystatin from Onchocerca volvulus, Nippocystatin from
Nippostrongylus brasiliensis and Bm-CPI-1 from Brugia malayi are related to the cystatin family 2 of the cystatin superfamily (see Maizels et al., 2001). The
F. hepatica multi-domain cystatin, however, is structurally related to the kininogen family (or cystatin family 3) but may be the first-described member of a
new cystatin family.
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response predominates (Mulcahy et al., 1999). However, at
high levels of infection in mice (approximately 15
metacercariae) a marked suppression of Th1 responses
was observed (O’Neill et al., 2000). Moreover, when mice
were concurrently infected with F. hepatica and Bordetella
pertussis, the Th1-specific response to the bacterial
pathogen (assessed by measuring IFN-g) was suppressed.
This suppression led to a delay in the clearance of the
bacterium in the co-infected mice as compared to mice
infected with B. pertussis alone (Brady et al., 1999). Liver
fluke infection also suppressed the Th1 responses to a
B. pertussis whole cell vaccine (WCV) suggesting that the
parasite may secrete Th1 suppressive factors. Subsequently,
O’Neill et al. (2001) demonstrated that injection of purified
cathepsin L just prior to vaccination with B. pertussis WCV
blocked the production of IFN-g by WCV-stimulated spleen
cells. It is possible, therefore, that secreted cathepsin Ls play
some immunomodulatory/immunosuppressive function by
blocking the development of protective Th1 responses in the
host and thus aiding the progression of non-protective Th2
responses that would favour the longevity of the parasite.
6. Vaccine trials with cathepsin L proteases
The involvement in biological roles that are essential to
the parasite’s survival in the host makes the F. hepatica
cathepsin L proteases likely targets at which novel vaccines
could be directed. Native FheCL1 and FheCL2 proteases
could be purified from the ES products of adult worms by a
series of conventional gel permeation and ion exchange
chromatography steps and produced in sufficient quantities
to allow experimental vaccine trials in cattle. In our first
vaccine trial a dose-ranging experiment demonstrated that
significant protection against liver fluke infection (average
54%) could be obtained and that doses of as little as 10 mg of
protein, given on three occasions, could induce protective
responses (Dalton et al., 1996). Subsequent trials, performed
with 200 mg per dose, confirmed the protective nature of the
cathepsin L proteases (Table 1). When the cathepsin L
proteases were administered in conjunction with other liver
fluke antigens, such as a haem-binding protein, protection
levels of 73% were achieved (Dalton et al., 1996, Table 1).
A further vaccine trial in cattle showed that a combination
of FheCL1 and FheCL2 elicited 53% protection against
challenge, and trials in sheep induced protection levels from
33 to 60% (Mulcahy et al., 1998; Piacenza et al., 1999,
Table 1). When FheCL1 and FheCL2 were combined with
F. hepatica leucine aminopeptidase (LAP) protection levels
were 79% in sheep (Piacenza et al., 1999).
Additional beneficial aspects of the protection induced
by the cathepsin L vaccines were observed. First, in all
vaccine trials the proportion of liver flukes that did not
develop to maturity was greater in vaccinates than in non-
vaccinated controls. Consequently, the damage to the host’s
liver during acute infection was significantly reduced.
Secondly, vaccination of both sheep and cattle also elicited
a highly significant reduction (50–98%) of the parasite’s
ability to produce eggs, and those eggs that were synthesised
showed reduced ‘hatch rates’ (Dalton et al., 1996; Mulcahy
et al., 1998; Table 1). The implications of these findings are
that by reducing the parasite burden of the host and, at the
same time, blocking the synthesis of viable eggs by those
parasites that do survive in vaccinated animals, the vaccine
would have a profound effect on pasture contamination and
hence disease transmission.
7. What is the mechanism behind protection?
Studies examining the immune responses of cattle that
were given either experimental or natural infections of
F. hepatica metacercariae showed that animals generate
IgG1 antibodies and little or no IgG2 antibodies
Table 1
Summary of vaccine trials with F. hepatica cathepsin L proteases
Antigen Host Dose Protection (%) Reduction in
viable eggs (%)
FheCL1a Cattle 10–200 mg £ 3 38.2–69.4 ND
FheCL1a Cattle 200 mg £ 3 43 40–65
FheCL1 þ haem fractiona Cattle 200 mg £ 3 52 80
FheCL1 þ haem fractiona Cattle 200 mg £ 3 72.4 98
FheCL1 þ FheCL1b Cattle 200 mg £ 3 54 55
FheCL1c Sheep 100 mg £ 2 34 71
FheCL2c Sheep 100 mg £ 2 33 81
FheCL2 þ FheCL2c Sheep 100 mg each £ 2 60 ND
FheCL2 þ FheCL2 þ LAPc Sheep 100 mg each £ 2 79 ND
FheCL proteasesd Sheep 120 þ 90 mg 0 69.4
ND, not determined.
a Dalton et al. (1996).
b Mulcahy et al. (1998).
c Piacenza et al. (1999).
d Wijffels et al. (1994).
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(Mulcahy et al., 1999; Hoyle et al., 2002). These
observations suggest that the immune responses to liver
fluke antigens are highly polarised to a Th2 type. On the
other hand, antibody responses to the cathepsin L-based
vaccines include high titres of both IgG1 and IgG2
indicating that protection is associated with the induction
of a Th1 responses or a mixed Th1/Th2 response (Mulcahy
et al., 1998, 1999).
A recent analysis of the cathepsin L-specific IgG1
antibody responses in infected cattle revealed that these
antibodies do not appear in the serum until 4 or 5 weeks
post-infection. Moreover, animals given a second infection
4 weeks after the primary infection did not exhibit any
boosting of immune responses to the cathepsin L proteases
(Hoyle et al., 2002; Fig. 5). It is clear, therefore, that
cathepsin Ls are not highly immunogenic in the early stages
of infection such that, at this stage, they may be considered
‘hidden antigens’. This may be an important strategy used
by the parasite to prevent antibodies being generated to
critical molecules. Accordingly, vaccinating animals with
cathepsin Ls would elicit a high titre of anti-cathepsin L
antibodies that would upset this evasion strategy and,
therefore, would be detrimental to the early migratory stages
of the parasite. Indeed, when animals are vaccinated with
cathepsin L a positive correlation was observed between
protection and antibody titres (Mulcahy et al., 1998; Fig. 6).
The effects of the vaccine on egg production and ‘hatch
rate’ may be mediated by antibodies that inhibit parasite
feeding by blocking cathepsin L activity, thereby preventing
the acquisition of amino acids for the synthesis of egg
proteins. Additionally and/or alternatively, since cathepsin
Ls have been immunolocalised to the reproductive
organs of the mature parasite (Spithill et al., 1999a;
Wijffels et al., 1994) and may play a role in egg production,
vaccine-induced antibodies may inhibit the enzyme and
thereby have a direct effect on female reproductive
structures.
While antibodies seem to be central to the protective
effects of the cathepsin L vaccine, it is clear that the
generation of a Th1 or Th1/Th2 type immune response is
also critical. The induction of this type of response was
dependant on the adjuvant employed in our studies i.e.
Freund’s Complete/Incomplete Adjuvant. However, it also
seems likely that by blocking cathepsin L activity the
vaccine prevents the parasite from suppressing the Th1
response of the host and from inducing the development of
Th2 responses that are typical of natural infections.
8. Functional expression of cathepsin L proteases
While FheCL1 and FheCL2 could be purified from liver
fluke ES products in quantities that allowed the detailed
analysis of their biochemical and physico-chemical proper-
ties, and their assessment as vaccine candidates, it is
obvious that for their future commercialisation a method of
recombinant production is necessary. The production of
cathepsin L proteases in a fully functional form requires
expression of the pro-mature form of the enzyme since the
pro-peptide region is required for correct folding of the
molecule. Prokaryotic systems of expression, e.g. E. coli,
are not suitable for the production of functionally active
cathepsin proteases, although these systems have been
employed to express non-active proteins, such as
F. gigantica cathepsin L (Yamasaki et al., 2002), which
were subsequently re-folded to active form. Unfortunately,
re-folding methodologies are complex, cumbersome and
expensive, and serve to obviate their application in
commercial production schemes.
Fig. 5. IgG1 antibody response of experimental-infected cattle to FheCL1.
Cattle were experimentally infected with metacercariae of F. hepatica
either once (solid arrow) or twice (4 weeks apart, dotted arrows). Serum
was collected weekly and assayed by ELISA for IgG1 antibodies to purified
FheCL1 (IgG2 antibodies were either very low or undetectable). Antibody
responses to FheCL1 in both experimental groups were observed 4–5
weeks after the primary infection.
Fig. 6. Immune responses of FheCL1-vaccinated and non-vaccinated
control cattle. Relationship between antibody titres and numbers of liver
fluke recovered from livers of non-vaccinated animals and cattle vaccinated
with cathepsin L proteases. In vaccinated animals, high total antibody titres
(diamonds) correlate with lower fluke burdens (these antibodies consist of
both IgG1 and IgG2). In contrast, in non-vaccinated control animals
(circles) high antibody titres correlate with higher infections (these
antibodies consist predominantly of IgG1, see text).
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Yeast systems have proved more successful for the
functional expression of many parasite proteases including
the F. hepatica cathepsin Ls (Dalton et al., in press). We
have reported that the yeast Saccharomyces cerevisiae,
transformed with a full-length FheCL1 or FheCL2 cDNA,
expressed and secreted functional enzyme into the culture
medium from which homogeneous enzyme could be
obtained by conventional purification techniques such as
gel filtration and ion exchange chromatography (Dowd et al.,
1997; Roche et al., 1997). While the functional expression
of mammalian cathepsin proteases in S. cerevisiae has also
been reported, these have necessitated the use of an a-factor
pre- or pre-pro-signals. However, functional expression of
FheCL1 and FheCL2 did not require such a fusion protein
and N-terminal sequencing of expressed proteases revealed
that they were processed in yeast to the mature enzyme by
cleavage at the precise position as that observed for the
native enzymes (Dowd et al., 1997; Roche et al., 1997).
Notwithstanding these advances, the expression of cathe-
spin L protease was low (approximately 100 mg/l) and
hence still not suitable for large-scale production. More
recently, however, we have employed the yeast Pichia
pastoris for protease expression using vectors that include
the yeast a-factor pre-pro-signals (Invitrogen). High-level
expression of FheCL1 has been achieved (800 mg/l) and the
protease, which carries a His6 tag, can be isolated by a one-
step affinity chromatography procedure on Ni-NTA-agarose
(Fig. 1). The protease is expressed as a pro-enzyme together
with a semi-processed form, both of which can be activated
at low pH to fully active mature enzyme (Fig. 1). The
physico-chemical properties (substrate specificity, pH
optima, stability, etc.) and molecular size of cathespin L
are similar to the native enzyme, and more importantly with
respect to vaccines, no post-translational glycosylation
occurs (unpublished data). These experiments demonstrate
that liver fluke FheCL1 and FheCL2 could be produced at a
commercial level using yeast as the heterologous expression
system.
9. Concluding remarks
In our laboratory the cathepsin L proteases of F. hepatica
have given consistent positive results when used as vaccines
against fasciolosis in cattle and sheep and therefore have
excellent prospects for the development of first generation
anti-fluke vaccines. Vaccinations in sheep with a purified
fraction of cysteine proteases of adult F. hepatica carried
out by Wijffels et al. (1994), however, did not provide any
protection against a challenge infection, although a .70%
reduction of faecal eggs counts (FEC) was observed
(Table 1). In addition, vaccination trials in cattle with
F. gigantica cathepsin Ls did not protect animals against
this fluke species (Spithill et al., 1999a). The dis-
crepancies remain unresolved and may only be resolved if
a comparative analysis of the immune responses to
the vaccines was carried out. There are differences in
vaccine formulations, doses and/or route of administration
between the trials (see Spithill et al., 1999a,b) that may have
induced a variety of effector mechanisms to the vaccines.
Each of these factors will need to be investigated system-
atically during the developmental stages of a commercial
vaccine.
Besides the cathepsin L proteases there are several other
molecules that are potential vaccine candidates including
GST, FABP (Spithill and Dalton, 1998) and LAP (Piacenza
et al., 1999). While trials with these antigens have given
some very variable results, no detailed analysis of immune
responses to the vaccines has been carried out to determine
immunological factors that correlate with protection/no
protection. It is therefore still feasible that these molecules
could be realised as a basis for commercial vaccines, either
alone or in combination with other candidates, if the precise
conditions for inducing protection were elucidated.
The commercialisation of a vaccine will require a system
for production and downstream processing that is not so
costly as to reduce the final product’s competitiveness
against current drug treatments. Both E. coli and yeast
expression systems may be suitable for the production of
vaccines for experimental trials, but before progressing into
developmental phase the best/cheapest system for up-scale
production/downstream processing will have to be con-
sidered for final commercialisation in an animal health
market that already suffers from relatively low-valued/low
profit-margin products (Dalton et al., in press). Never-
theless, the prospects for future vaccines are good,
particularly considering the pressure on the industry to
move away from chemical treatments.
References
Andrews, S.J., 1999. The life cycle of Fasciola hepatica. In: Dalton, J.P.,
(Ed.), Fasciolosis, CAB International, Wallingford, UK, pp. 1–30.
Anon., 18 March 1995. Resistance to fluke drug found on Sligo farm. Irish
Farmer’s J. 2.
Barrett, A.J., Kirschke, H., 1981. Cathespin B, cathepsin H and cathepsin L.
Methods Enzymol. 80, 535–561.
Berasain, P., Goni, F., McGonigle, S., Dowd, A., Dalton, J.P., Frangione,
B., Carmona, C., 1997. Proteinases secreted by Fasciola hepatica
degrade extracellular matrix and basement membrane components.
J. Parasitol. 83, 1–5.
Brady, M.T., O’Neill, S.M., Dalton, J.P., Mills, K.H.G., 1999. Fasciola
hepatica suppresses protective Th1 responses against Bordetella
pertussis. Infect. Immun. 67, 5372–5378.
Carmona, C., Dowd, A.J., Smith, A.M., Dalton, J.P., 1993. Cathespin L
proteinase secreted by Fasciola hepatica in vitro prevents antibody-
mediated eosinophil attachment to newly excysted juveniles. Mol.
Biochem. Parasitol. 62, 9–18.
Dalton, J.P., Heffernan, M., 1989. Thiol proteases released in vitro by
Fasciola hepatica. Mol. Biochem. Parasitol. 35, 161–166.
Dalton, J.P., McGonigle, S., Rolph, T.P., Andrews, S.J., 1996. Induction of
protective immunity in cattle against infection with Fasciola hepatica
by vaccination with cathepsin L proteinase and haemoglobin. Infect.
Immun. 64, 5066–5074.
J.P. Dalton et al. / International Journal for Parasitology 33 (2003) 1173–11811180
Dalton, J.P., Brindley, P.J., Knox, D.P., Hotez, P.J., Brady, C.P., Donnelly,
S., O’Neill, S.M., Mulcahy, G., Loukas, A., 2003. Helminth vaccines:
from mining genomic information for vaccine targets to systems used
for protein expression. Int. J. Parasitol, 33, 621–640.
Dowd, A.J., Dooley, M., Fagain, C., Dalton, J.P., 2000. Stability studies on
the cathepsin L proteinase of the helminth parasite, Fasciola hepatica.
Enzyme Microb. Technol. 27, 599–604.
Dowd, A.J., Smith, A.M., McGongle, S., Dalton, J.P., 1994. Purification
and characterisation of a second cathepsin L proteinase secreted by the
trematode Fasciola hepatica. Eur. J. Biochem. 223, 91–98.
Dowd, A.J., Tort, J., Roche, L., Dalton, J.P., 1997. Isolation of a cDNA
encoding cathepsin L2 and functional expression in Saccharomyces
cerevisiae. Mol. Biochem. Parasitol. 88, 163–174.
Fairweather, I., Boray, J.C., 1999. Mechanism of fasciolicide action and
drug resistance in Fasciola hepatica. In: Dalton, J.P., (Ed.), Fasciolosis,
CAB International, Wallingford, UK, pp. 225–276.
Gaasenbeek, C.P.H., Moll, L., Cornelissen, J.B.W.J., Vellema, P.,
Borgsteede, F.H.M., 2001. An experimental study on triclabendazole
resistance of Fasciola hepatica in sheep. Vet. Parasitol. 95, 37–43.
Grams, R., Vichasri-Grams, S., Sobhorn, P., Upatham, E.S., Viyanant, V.,
2001. Molecular cloning and characterisation of cathepsin L encoding
genes from Fasciola gigantica. Parasitol. Int. 50, 105–114.
Heussler, T.V., Dobbelaere, A.E.D., 1994. Cloning of a protease gene
family of Fasciola hepatica by the polymerase chain reaction. Mol.
Biochem. Parasitol. 64, 11–23.
Hoyle, D.V., Dalton, J.P., Chase-Topping, M., Taylor, D.W., 2002. Pre-
exposure of cattle to drug-abbreviated Fasciola hepatica infections: the
effect upon subsequent challenge infection and early immune response.
Vet. Parasitol. 111, 65–82.
Jefferies, J.R., Campbell, A.M., van Rossum, A.J., Barrett, J., Brophy, P.M.,
2001. Proteomic analysis of Fasciola hepatica excretory–secretory
products. Proteomics 1, 1128–1132.
Mas-Coma, S., Bargues, M.D., Esteban, J.G., 1999. Human fasciolosis. In:
Dalton, J.P., (Ed.), Fasciolosis, CAB International, Wallingford, UK,
pp. 411–434.
Maizels, R.M., Gomez-Escobar, N., Gregory, W.F., Murray, J., Zang, X.,
2001. Immune evasion genes from filarial nematodes. Int. J. Parasitol.
31, 889–898.
Mitchell, G.B.B., Maris, L., Bonniwell, M.A., 1998. Triclabendazole-
resistant liver fluke in Scottish sheep. Vet. Rec. 143, 399.
Moll, L., Gassenbeek, C.P.H., Vellema, P., Borgsteede, F.H.M., 2000.
Resistance of Fasciola hepatica against triclabendazole in cattle and
sheep in the Netherlands. Vet. Parasitol. 91, 153–158.
Mulcahy, G., O’Connor, F., McGonigle, S., Dowd, A.J., Clery, D.,
Andrews, S.J., Dalton, J.P., 1998. Correlation of specific antibody titre
and avidity with protection in cattle immunized against Fasciola
hepatica. Vaccine 16, 932–939.
Mulcahy, G., Joyce, P., Dalton, J.P., 1999. Immunology of Fasciola
hepatica infection. In: Dalton, J.P., (Ed.), Fasciolosis, CAB Inter-
national, Wallingford, UK, pp. 341–376.
O’Neill, S.M., Parkinson, M., Strauss, W., Angles, R., Dalton, J.P., 1998.
Immunodiagnosis of Fasciola hepatica infection (fascioliasis) in a
human population in the Bolivian altiplano using purified cathepsin L
cysteine protease. Am. J. Trop. Med. Hyg. 58, 417–423.
O’Neill, S.M., Brady, M.T., Callanan, J.J., Mills, K.H.G., Dalton, J.P.,
2000. Fasciola hepatica infection down-regulates Th1 response in
mice. Parasite Immunol. 22, 147–155.
O’Neill, S.M., Mills, K.H.G., Dalton, J.P., 2001. Fasciola hepatica
cathepsin L cysteine proteinase suppresses Bordetella pertussis-specific
interferon-g production in vivo. Parasite Immunol. 23, 541–547.
Overend, D.J., Bowen, F.L., 1995. Resistance of Fasciola hepatica to
triclabendazole. Aust. Vet. J. 72, 275–276.
Piacenza, L., Acosta, D., Basmadjian, I., Dalton, J.P., Carmoma, C., 1999.
Vaccination with cathepsin L proteinases and with leucine aminopepti-
dase induces high levels of protection against fascioliasis in sheep.
Infect. Immun. 67, 1954–1961.
Roche, L., Dowd, A.J., Tort, J., McGonigle, S., McSweeney, A., Curley, P.,
Ryan, T., Dalton, J.P., 1997. Functional expression of Fasciola hepatica
cathepsin L1 in Saccharomyces cerevisiae. Eur. J. Biochem. 245,
373–380.
Rokni, M.B., Massoud, J., O’Neill, S.M., Parkinson, M., Dalton, J.P., 2002.
Diagnosis of human fasciolosis in the Gilan province of northern Iran:
application of cathepsin L-ELISA. Diagn. Microbiol. Infect. Dis. 44,
175–179.
Smith, A.M., Dowd, A.J., McGonigle, S., Keegan, P.S., Brennan, G.,
Trudgett, A., Dalton, J.P., 1993. Purification of a cathepsin L proteinase
secreted by adult Fasciola hepatica. Mol. Biochem. Parasitol. 62, 1–8.
Spithill, T.W., Dalton, J.P., 1998. Progress in the development of liver fluke
vaccines. Parasitol. Today 14, 224–228.
Spithill, T.W., Smooker, P.M., Sexton, J.L., Bozas, E., Morrison, C.A.,
Creaney, J., Parsons, J.C., 1999a. Development of vaccines against
Fasciola hepatica. In: Dalton, J.P., (Ed.), Fasciolosis, CAB Inter-
national, Wallingford, UK, pp. 377–401.
Spithill, T.W., Smooker, P.M., Copeman, D.B., 1999b. Fasciola gigantica:
epidemiology, control, immunology and molecular biology. In: Dalton,
J.P., (Ed.), Fasciolosis, CAB International, Wallingford, UK, pp.
465–526.
Tkalcevic, J., Ashman, K., Meeusen, E.N.T., 1995. Fasciola hepatica:
rapid identification of newly excysted juvenile proteins. Biochem.
Biophys. Res. Commun. 213, 169–174.
Tort, J., Brindley, P.J., Knox, D., Wolfe, K.H., Dalton, J.P., 1999. Helminth
proteinases and their associated genes. Adv. Parasitol. 43, 161–266.
Wijffels, G.L., Salvatore, L., Dosen, M., Waddington, J., Thompson, C.,
Campbell, N., Sexton, J., Wicker, J., Bowen, F., Friedel, T., Spithill,
T.W., 1994. Vaccination of sheep with purified cysteine proteinases of
Fasciola hepatica decreases worm fecundity. Exp. Parasitol. 78,
132–148.
Yamasaki, H., Mineki, R., Murayama, F., Ito, A., Aoki, T., 2002.
Characterisation and expression of the Fasciola gigantica cathepsin L
gene. Int. J. Parasitol. 32, 1031–1042.
J.P. Dalton et al. / International Journal for Parasitology 33 (2003) 1173–1181 1181
